Clinical Trials Arena on MSN18d
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of overall ...
pharmaphorum1d
Seagen wins Enhertu patent dispute with Daiichi Sankyo
Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds ...
pharmaphorum1y
WCLC: Daiichi Sankyo HER3 ADC readout sets up filings
Already-marketed HER2-targeting ADC Enhertu (trastuzumab deruxtecan) has a boxed warning on its label for ILD, but that has not stopped the drug's rapid growth. Nevertheless, ILD continues to take ...